Latest filings (excl ownership)
10-Q
2024 Q2
Quarterly report
12 Aug 24
8-K
Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update
12 Aug 24
8-K
Submission of Matters to a Vote of Security Holders
13 Jun 24
424B5
Prospectus supplement for primary offering
14 May 24
10-Q
2024 Q1
Quarterly report
14 May 24
8-K
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
14 May 24
8-K
Departure of Directors or Certain Officers
30 Apr 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Departure of Directors or Certain Officers
25 Apr 24
S-3ASR
Automatic shelf registration
3 Apr 24
S-3ASR
Automatic shelf registration
3 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Immunome Reports Full-Year 2023 Financial Results and Provides Update on Recently Acquired Assets
28 Mar 24
8-K
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
26 Mar 24
8-K
Other Events
14 Feb 24
424B5
Prospectus supplement for primary offering
14 Feb 24
424B5
Prospectus supplement for primary offering
13 Feb 24
8-K
Results of Operations and Financial Condition
13 Feb 24
S-3ASR
Automatic shelf registration
13 Feb 24
8-K
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
6 Feb 24
S-8
Registration of securities for employees
2 Feb 24
8-K
Departure of Directors or Certain Officers
31 Jan 24
8-K
Regulation FD Disclosure
11 Jan 24
8-K
Entry into a Material Definitive Agreement
8 Jan 24
8-K
Departure of Directors or Certain Officers
2 Jan 24
8-K
Departure of Directors or Certain Officers
29 Dec 23
8-K
Other Events
26 Dec 23
EFFECT
Notice of effectiveness
28 Nov 23
8-K/A
Report of Independent Auditors
22 Nov 23
CORRESP
Correspondence with SEC
22 Nov 23
UPLOAD
Letter from SEC
20 Nov 23
S-3
Shelf registration
16 Nov 23
8-K
Regulation FD Disclosure
15 Nov 23
8-K
Immunome Reports Third Quarter 2023 Financial Results
9 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Departure of Directors or Certain Officers
8 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Nov 23
8-K
Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies
4 Oct 23
Latest ownership filings
4
Max Rosett
20 Sep 24
144
Notice of proposed sale of securities
19 Sep 24
SC 13D/A
Barchas Isaac
21 Aug 24
4
JEAN JACQUES BIENAIME
19 Aug 24
4
Jack Higgins
19 Aug 24
144
Notice of proposed sale of securities
15 Aug 24
4
CLAY B SIEGALL
13 Aug 24
4
Sandra G. Stoneman
13 Aug 24
4
Kinney Horn
13 Aug 24
4
Bruce Turner
13 Aug 24
4
Max Rosett
13 Aug 24
4
Robert Lechleider
13 Aug 24
4
Jack Higgins
13 Aug 24
4
Philip Tsai
18 Jun 24
3
Philip Tsai
18 Jun 24
4
James P Boylan
18 Jun 24
4
CAROL SCHAFER
18 Jun 24
4
SANDRA M SWAIN
18 Jun 24
4
PHILIP WAGENHEIM
18 Jun 24
4
JEAN JACQUES BIENAIME
18 Jun 24
4
Isaac Barchas
18 Jun 24
4
JEAN JACQUES BIENAIME
22 May 24
4
CLAY B SIEGALL
21 May 24
4
Max Rosett
17 May 24
4
SANDRA M SWAIN
29 Apr 24
3
SANDRA M SWAIN
29 Apr 24
4
Kinney Horn
21 Feb 24
3
Kinney Horn
21 Feb 24
SC 13G/A
Alpine Global Management, LLC
12 Feb 24
SC 13G
FMR LLC
9 Feb 24
4
Max Rosett
31 Jan 24
4
Sandra G. Stoneman
31 Jan 24
3
Bob Lapetina
4 Jan 24
4
CAROL SCHAFER
4 Jan 24
3
CAROL SCHAFER
4 Jan 24
4
Phil Noland Roberts
15 Dec 23
3
Phil Noland Roberts
15 Dec 23
4
Jack Higgins
5 Dec 23
4
JEAN JACQUES BIENAIME
9 Nov 23
3
JEAN JACQUES BIENAIME
9 Nov 23